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Thyroid hormone (triiodothyronine, T3) is known to activate
transcription by binding heterodimers of thyroid hormone
receptors (TRs) and retinoid X receptors (RXRs). RXR-TRs
bind toT3 response elements (TREs) composed of direct repeats
of the sequence AGGTCA spaced by four nucleotides (DR-4). In
other TREs, however, the half-sites can be arranged as inverted
palindromes and palindromes (Pal). Here we show that TR
homodimers and monomers activate transcription from repre-
sentative TREs with alternate half-site placements. TR acti-
vates transcriptionmore efficiently thanTR at an inverted pal-
indrome (F2), and this correlates with preferential TR
homodimer formation at F2 in vitro. Furthermore, reconstruc-
tion of TR transcription complexes in yeast indicates that TR
homodimers are active at F2, whereas RXR-TRs are active at
DR-4 and Pal. Finally, analysis of TR mutations that block
homodimer and/or heterodimer formation revealTRE-selective
requirements for these surfaces in mammalian cells, which sug-
gest that TR homodimers are active at F2, RXR-TRs at DR-4,
and TR monomers at Pal. TR requires higher levels of hor-
mone for activation at F2 than other TREs, and this differen-
tial effect is abolished by a dimer surface mutation suggesting
that it is related to composition of the TRTRE complex. We
propose that interactions of particular TR oligomers with dif-
ferent elements play unappreciated roles in TRE-selective
actions of liganded TRs in vivo.
Thyroid hormone receptors (TR5 and TR) modulate gene
expression by binding to thyroid hormone response elements
(TREs) in target gene promoters (1–5). TR activity is primarily
regulated by thyroid hormone (as 3,5,3-triiodo-L-thyronine
(T3)), which alters the conformation of the receptor C-terminal
ligand-binding domain (LBD) to promote dissociation of core-
pressors and association of coactivators (6). Nevertheless, TR
activity is also influenced by the sequence, arrangement, and
promoter context of the TRE (2, 3). LigandedTRs activate tran-
scription from some TREs and repress transcription at others
(reviewed in Ref. 3 and see Refs. 7 and 8). In addition, TRE
sequence and arrangement influence the magnitude of
response to unliganded and liganded TRs, T3 concentration
dependence, dominant negative activities of mutants that arise
in resistance to thyroid hormone syndrome, and the direction
and extent of response to TR isoform-selective ligands
(9–13). Improvedunderstanding of themolecular basis of these
effects could help us to harness these selective activities.
TRs bind to DNA either as heterodimers with the closely
related retinoidX receptor (RXR) or as homodimers andmono-
mers, and each species exhibits preferences for different TREs
(reviewed in Refs. 1 and 2). TREs are composed of degenerate
repeats of the sequenceAGGTCA,with the half-sites arrayed as
direct repeats spaced by four nucleotides (DR-4), inverted
repeats spaced by four to six nucleotides (IPs) or palindromes
(Pal). Heterodimers of RXRs and TRs bind each of these ele-
ments, with a strong preference for DR-4. In contrast, TR
homodimers bind strongly to IP elements, weakly to DR-4, and
not all to Pal (9, 14–17), and TR homodimers bind TREs, at
best, only weakly (18, 19). Finally, both TRs can bind to DNA
elements as monomers. The fact that different oligomeric
forms of TR bind to DNA and exhibit clear preferences for
different TREs raises the possibility that the nature of the
response element could influenceTR action andT3 response by
recruitment of distinct TR transcription complexes with
unique activities.
It is clear that RXR-TRs are important mediators of T3
action. TR binding to RXRs in vivo has been verified by obser-
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vations that TRs consistently copurify as complexes with RXRs
from cell and tissue extracts (1, 3). Moreover, analysis of RXR
knock-out mice reveals defective T3 responses (3, 20), and
RXRs and TRs synergize at direct repeats in cotransfection
experiments in some cell types (21, 22). Furthermore, native
TREs are often comprised of DR-4 elements, which bind pref-
erentially to RXR-TRs (1, 3), and in vitroDNA binding proper-
ties of RXR-TRs are consistent with roles in T3 response; RXR-
TRs form stable complexes with DNA that persist in the
presence of hormone (23–25). Finally, chromatin immunopre-
cipitation analysis confirms that RXR-TRs occupy DR-4 ele-
ments in the Xenopus laevis TR and thyroid hormone/bZIP
promoters at late stages of embryogenesis (26).
Potential roles of other TR oligomers are not as well under-
stood. An RXR gene knock-out fails to affect TR action in ear
development, implying that alternate TR species could regulate
this process (27). Moreover, the fact that unliganded TRs
repress transcriptionmore efficiently at IP elements than DR-4
elements has been attributed to preferential recruitment of
homodimers, which bind corepressors more efficiently than
RXR-TRs (9, 10, 28–30). Accordingly, it has been shown that
TR can bind to an unusual TRE in the human immunodefi-
ciency virus type 1 in the absence of RXR in the frog oocyte
chromatin assembly system (31). Roles of alternate forms of TR
in T3 activation are even less clear. Although the fact that TR
homodimers dissociate rapidly from cognate TREs and T3 sup-
presses homodimer formation on DNA has been taken as an
argument against a role for this species in T3 activation (1),
other studies reveal that TR-TRDNA complexes are stabilized
by coactivators (32) and that T3 response at IP-6 elements is
often independent of coexpressed RXR in transfections (9, 33).
Most strikingly, a recent study revealed that RXR expression
was only required for optimal T3 response at subsets of posi-
tively regulated genes in a mouse preneuronal cell line (34).
Thus, there are several indications that alternate TR oligomers
contribute to T3 induction.
Study of the actions of different TR oligomers inmammalian
cells is often complicated by endogenous expression of RXR
and NR coregulators. To overcome this difficulty, we (35–38)
and others (39) have examined TR action in the yeast Saccha-
romyces cerevisiae.This species is devoid of knownNRs andNR
coregulators and can be used to reconstruct defined TR tran-
scription complexes in a eukaryotic cell background. These
studies indicate that TRs indeed activate transcription at
selectedTREs in the absence of RXR (35, 39) and that the extent
of TRhomodimer formation to differentDR-4 elements in vitro
correlates with T3 response (39).
RXR-TR heterodimer and TR homodimer surfaces have also
been defined. There are contacts between respective LBDs and
DBDs of RXRs and TRs (1), whereas TR homodimer formation
at DR-4 and IP-6 relies exclusively on LBD-LBD contacts (14,
40–42). We used x-ray structure-directed mutagenesis to
define these surfaces and showed that RXR-TR heterodimer
and TR homodimer formation requires a small hydrophobic
patch at the junction of helices (H) 10 and H11 in the LBD (17,
43). This surface (LBD dimer surface) resembles those seen in
x-ray structures of other NR LBD heterodimers and
homodimers (reviewed in Ref. 2). The TR interface (DBD het-
erodimer surface) that contacts the RXR DBD was detected in
an x-ray structure of an RXRTR DBD complex on a DR-4
element (44), and mutation of this surface inhibits RXR-TR
heterodimer formation at DR-4 in vitro (17). The same struc-
ture reveals another difference between TRs and RXRs; the
TR DBD contains an -helical C-terminal extension (CTE)
that is absent fromRXR andmediates additional DNA contacts
(44). The requirements for these surfaces in T3 response in vivo
are not known.
In this study, we compare actions of wild type and mutant
TRs at different TREs in yeast and in mammalian cells.
Although the data confirm that RXR-TRs activate transcription
at DR-4, they suggest that TR homodimers and monomers
mediate T3 response at IP-6 and Pal, respectively. We propose
that TRE half-site orientation dictates the composition of
the active form of TR in vivo and that this effect should be
considered in analysis of TR activity and design of selective
TR modulators.
MATERIALS ANDMETHODS
Plasmids—The following plasmids have been described pre-
viously: T3-inducible -galactosidase reporters for yeast tran-
scription assays, TRE-F2x1, TRE-DR-4x1, and TRE-Palx1 and
yeast (YEp56) expression vectors for wild type TR, RXR, and
GRIP1 (35–38); T3-inducible reporters containing two copies
of each TRE driving luciferase expression and a similar 9-cis-
retinoic acid-responsive reporter containing two copies of a
DR-1 element and mammalian (pCMX) expression vectors for
TR, TRL422R, and RXR (17).
New TR mutants reported in these studies (pCMX vectors
TR4XDBD (D104A, Y117A, R120A, andD177A), TR3XLBD
(L400R, L422R, and M423R), TR4XDBD3XLBD, TR T-box
deletion (deletion of 6 amino acids from175 to 180 in theT-box
region, -ATDLVL) and the yeast Yep56 vector TRL422Rwere
created in existing vectors using QuikChange site-directed
mutagenesis kits (Stratagene). The presence of the mutation(s)
was verified by DNA sequencing using Sequenase kits (Strat-
agene). FLAG andMyc-tagged TR expression vectors were cre-
ated by PCR amplification of the TR cDNA and insertion into
FLAG and Myc vectors (Clontech) at appropriate restriction
sites.
Mammalian Cell Culture, Electroporation, and Luciferase
Assays—Human promonocyte U937, HEK, HeLa, and U2-OS
cells were maintained at 37 °C, 5% CO2 subcultured in media
RPMI 1640 with 10% newborn bovine serum, 2 mM glutamine,
50 units/ml penicillin, and 50 g/ml streptomycin. Transfec-
tions were carried out as described previously (45). After incu-
bation for 24 h at 37 °C with ethanol or T3, cells were collected
by centrifugation, and the pellets were solubilized by addition
of 150 l of 0.25 M Tris-HCl, pH 7.6, containing 0.1% Triton
X-100. Luciferase activity was analyzed by standard methods
(luciferase assay system, Promega).
Gel Shifts—For Fig. 1, TRs were labeled with [35S]methi-
onine, and complex formationwasmeasured at unlabeledTREs
in a 20-l reaction with 1 g of poly(dI-dC) (Amersham Bio-
sciences) (17). The binding buffer contained 25 mM HEPES, 50
mMKCl, 1mMdithiothreitol, 10MZnSO4, 0.1%Nonidet P-40,
5% glycerol. After 30min at room temperature, themixturewas
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loaded onto a 5% nondenaturing polyacrylamide gel that was
previously run for 30min at 200 V. TR and RXRTRDNA com-
plexes were visualized as follows: the gel was run at 4 °C for
120–180 min at 200 V in a running buffer containing 45 mM
Tris borate, pH 8.0, and 1 mM EDTA, fixed, dried, and exposed
to autoradiography. For other figures, binding of TRs and RXR-
TRs to DNA was assayed as described previously (43), by mix-
ing 20 fmol of TRs  RXRs with 300,000 cpm of [-32P]ATP-
radiolabeled TRE oligonucleotide.
Yeast Strains and Transcriptional Analysis—The S. cerevi-
siae strain YPH499 (MAT, ura3, lys2, ade2, trp1, his3, leu2)
was used for most transformations. For reporter assays, trans-
formants were grown in minimal medium (0.67% yeast nitro-
gen base, 2% glucose) supplemented with adenine and lysine
(both at 40mg/liter), as described previously (35–38). The yeast
transformants were isolated and grown in the appropriatemin-
imal medium with added supplements as required. Cells were
grown overnight with T3 at a final concentration of 1 M, har-
vested, washed, resuspended in Z buffer, and lysed with glass
beads (425–600 m) before centrifugation. The supernatant
was collected, and the protein concentration was determined
by the Lowry method using bovine serum albumin as a stand-
ard. Twenty micrograms of protein were used for the -galac-
tosidase assay, and transcriptional activities were expressed as
Miller units/mg of protein, as described previously (35–38).
Data shown were pooled from three independent experiments
and calculated as the means S.E.
Cell Extracts, Immunoprecipitation, and Western Blotting—
HeLa cells were cotransfected with 5 g of pCMV-Myc-TR1
and 5 g of pCMV-Tag2B-FLAG-TR1 by electroporation at
240 V and 950 microfarads. 24 h after transfection, cells were
washedwith phosphate-buffered saline and harvested. Samples
of whole cell extracts were lysed in RIPA buffer (50mMTris, pH
8.1, 150mMNaCl, 0.2% SDS, 1% sodiumdeoxycholate, 1%Non-
idet P-40, 5 mM EDTA) containing protease inhibitor mixture
(Calbiochem) and 1 mM phenylmethylsulfonyl fluoride at 4 °C
for 1 h, sonicated, and then centrifuged at 20,000 g for 15min.
100l (400g of total protein) of supernatant was diluted with
500 l of phosphate-buffered saline, and 4 g of rabbit anti-
FLAG antibody (Rockland, Inc.) was added. After incubation
overnight at 4 °C, 50 l of protein G-Sepharose beads (Amer-
sham Biosciences) were added to each sample, and the lysates
were incubated for 1 h at 4 °C. The beads then were washed six
timeswithTBS-T (Tris-buffered saline; 25mMTris, pH 8.3, 192
mM glycine, containing 0.05%Tween 20), suspended in 2 SDS
sample buffer containing 5% -mercaptoethanol, heated for 10
min at 95 °C, and resolved on 8% denaturing polyacrylamide
gels. After transferring to Immun-Blot polyvinylidene difluo-
ride membranes (Bio-Rad), the membranes were blocked with
5% nonfat milk in TBS-T and incubated with primary antibody,
mouseMyc-TR1 antibody (Clontech), at 1:1000 (w/v) dilution
in 1% nonfat milk in TBS-T. After washing with TBS-T, immu-
noblots were incubated with horseradish peroxidase-conju-
gated goat anti-mouse-IgG (Santa Cruz Biotechnology) in 1%
TBS-T, and proteins were visualized using enhanced chemilu-
minescence according to the manufacturer’s instructions
(Amersham Biosciences).
RESULTS
TR, but Not TR, Is Superactive at an IP-6 Element (F2)—
First, we first compared the actions of two major hormone-
binding TR isoforms (TR1 and TR1) at TRE-dependent
reporters in cell culture (Fig. 1A). TR gave significantly larger
T3 responses at an IP-6 element (F2) than TR, 30–40-fold
versus 6-fold. By contrast, the two TR isoforms gave compara-
ble T3 responses at a DR-4 element (4–5-fold), and T3
responses were weaker with TR at Pal (2–3-fold versus 4–5-
fold for TR).Western blotting of transfected cell extracts with
an antibody against an N-terminal FLAG tag in both TRs
revealed similar expression levels (Fig. 1A, inset). Moreover,
varying the amounts of TR expression vector confirmed that
differential effects were not related to differences in amounts of
TR required for optimal activation at each element (not shown).
Analysis of DNA binding preferences of TRs and RXR-TRs
confirms that TR homodimerizes on DNA in vitro and that
TR does not (Fig. 1B). TR homodimers bind strongly to F2
and, to a lesser extent, to DR-4. As expected, T3 inhibited TR
homodimer formation at both elements, although significant
residual binding of ligandedTR at F2was detected in the pres-
ence of hormone. In the same gels, TR and TR boundweakly
to all three TREs as monomers. Moreover, in parallel, both TRs
FIGURE 1. TR activates transcription strongly at F2 and binds as a
homodimer. A, results of transfection analysis in U2-OS cells, comparing
action of both TR isoforms at different TREs. Inset shows an image of a nylon
membrane blot of an SDS-polyacrylamide gel used to separate transfected
cell extracts and probed with an anti-FLAG tag antibody by Western blot.
B, x-ray autoradiographic image of non-denaturing gels used to separate
[35S]methionine-labeled TRs and RXR-TRs in complex with response element
oligonucleotides, F2, DR-4, and Pal. Images of TR-TR homodimers and TR
monomers are derived from different positions in the same gel. RXR-TR is
froma separate gel shift experiment run in parallel. Results are representative
of more than five experiments.
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formed heterodimers with RXR at all three TREs, with prefer-
ential binding to DR-4 (DR-4 F2 Pal). Thus, TR activates
transcription more efficiently at F2 than TR, and this corre-
lates with enhanced homodimer formation at F2 in vitro.
TRHomodimers Activate Transcription at F2 in Yeast—To
determine the extent to which different TR oligomers activate
transcription in eukaryotes, we assembled different TR tran-
scription complexes in yeast stably transfected with TRE-de-
pendent reporters and examined the effects of amutation in the
TR LBD dimer surface (TRL422R) in each context (17).
TRhomodimers andRXR-TRswere both active in yeast but
exhibited distinct TRE preferences (Fig. 2,A–C). In accordance
with our previous results, TR gave weak T3 response at all
three elements, regardless of the presence of coexpressed RXR,
and these responses were enhanced by GRIP1 (35). With TR
and GRIP1, large T3 responses were obtained at F2, and these
were inhibited by the TRL422R mutation (Fig. 2A). By con-
trast, T3 responses obtained with TR and GRIP1 at DR-4 and
Pal were smaller andwere enhanced by the samemutation (Fig.
2,B andC). Thus, TR-TR homodimers are active at F2, whereas
homodimer formation places a constraint on T3 response at
other elements. Although RXR did not enhance T3 response at
F2 (Fig. 2A), it potentiated T3 response about 7-fold at DR-4
(Fig. 2B) and about 2-fold at Pal (Fig. 2C). This RXR-dependent
effect required the TR LBD dimer surface, as RXR failed to
enhance activity of the TRL422Rmutant. Thus, RXR-TRs are
active atDR-4, andheterodimer formation provides amoderate
advantage for T3 response at Pal versus TR monomers.
It is unlikely that the TRL422R mutation inhibits T3
response via indirect effects on hormone binding or cofactor
recruitment. TRL422R does not exhibit reduced affinity for
T3 (17) and bound strongly to GRIP1 and other coactivators
in vitro (not shown). Thus, our data suggest that TR
homodimers are active at F2 in yeast and that RXR-TR het-
erodimers are active at DR-4 and, to some extent, at Pal. In
addition, the fact that TRL422R displays moderate activity at
all three TREs in the presence of GRIP1 implies that TRmono-
mers have the potential to activate transcription.
TRE-specific Requirements for TR LBD Dimer Surface in
Mammalian Cells—Next, we examined the role of the TR
LBD dimer interface at different TREs in mammalian cells. For
these experiments, we compared the effects of transfected TR
and TRL422R at different TREs in U937monocytes, which do
not express significant levels of TRs (45). We examined T3
response with a range of quantities of transfected TR and
TRL422R expression vectors to ensure detection of optimal
TR activity.
Wild typeTRs exhibited a similar activation profile at eachTRE
(Fig. 3,A–C). Peak induction of 30-fold at F2, 15-fold atDR-4, and
7-fold at Pal was obtained with 0.5–1.0 g of transfected TRs.
Moreover, higher levels ofTRs led to auto-inhibition (squelching),
although the extent of this effect varied. Unliganded TRs do not
repress transcription at theseminimal promoters to ameasurable
degree in these conditions (not shown).
In contrast, the effects of the TRL422R mutation were dif-
ferent at each TRE. TRL422R exhibited markedly reduced
activity relative towild typeTR at F2, at all levels of transfected
vector (Fig. 3A). The mutant also exhibited reduced activity at
DR-4, but this defect was overcome with higher amounts of
transfected TRL422R vector (Fig. 3B). Finally, TRL422R
activated transcription as efficiently as wild type TR at Pal, and
FIGURE2.TRhomodimersactivate transcriptionatF2 inyeast.A shows-ga-
lactosidase activities detected in extracts of yeast transformants stably trans-
fectedwithanF2-regulatedreporterand,as indicated,TR, TRL422R,RXR, and
GRIP1 and treatedwith vehicle or 1mMT3 (black bars).-Galactosidase activity is
expressed asMiller units/mgprotein. The data showa single determination that
is representative of the average of at least three experiments. B and C, as in A,
using aDR-4-regulated reporter (B) and Pal-regulated reporter (C).
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possibly even more efficiently at higher levels of transfected
vector (Fig. 3C). Similar results were also obtained with TR in
several other cell types, including HeLa, HEK, and U2-OS (not
shown).
To our knowledge, the data in Fig. 3 represent the first dem-
onstration that the TR LBD dimer surface is needed for opti-
mal T3 response inmammalian cells. Nevertheless, the fact that
there are TRE-selective requirements for this surface implies
that homodimer or heterodimer formation is required for opti-
mal response at F2 and DR-4 but not at Pal.
TRE-specific Requirements for TR DBD Heterodimer
Surface—Next, we assessed requirements for the TR DBD sur-
face that contacts the RXR DBD. To do this, we performed
transfections, as above, with vectors for TRs bearing mutations
at key residues in the DBD heterodimer surface (4XDBD) (44),
alone or in combination with a triple Arg substitution affecting
hydrophobic residues in the LBD dimer surface (3XLBD) (17).
We used relatively high levels of transfected TRs (2g) to high-
light different requirements for the LBD dimer surface at dif-
ferent TREs; in these conditions, TRL422R exhibits reduced
activity at F2, significant residual activity at DR-4, and elevated
activity at Pal (see Fig. 3).
Contributions of the DBD heterodimer surface and LBD
dimer surface vary at each TRE. TR action at F2 was absolutely
dependent upon the LBD dimer surface (TR 3XLBD), and
mutation of the DBD heterodimer interface had little effect
(Fig. 4A). By contrast, optimal TR action at DR-4 requires both
interfaces (Fig. 4B), mutation of the DBD heterodimer surface
(TR 4XDBD) or LBD dimer surface (TR 3XLBD) inhibited
TR activity by 35%, and mutation of both interfaces (TR
4XDBD and 3XLBD) inhibited TR activity by 70%. Finally, nei-
ther interface was required for T3 response at Pal (Fig. 4C).
Several conclusions can be derived from these studies. First,
the TR LBD dimer surface is required for T3 response at F2, but
the DBD heterodimer surface is not. Thus, TR homodimers are
active or RXR-TRs activate transcription in a configuration that
FIGURE 3. Requirements for the TR LBD dimer surface in mammalian cells.
A, F2. U937 cells were cotransfected with 4 g of F2 luciferase and increasing
concentrations (0.1, 0.5, 1.0, 2.0, and 4.0g) of TR or TRL422R expression vec-
tors and treated with vehicle or 100 nM T3. Data represent fold T3 inductions
obtainedateachamountofTRexpressionvectorandrepresenttheaverageofsix
experiments. B, as above, with DR-4-luciferase. Data were from six experiments.
C, as above, with Pal-luciferase. Datawere from four experiments.
FIGURE 4.DBDheterodimer surface is required for TR action at DR-4. Rel-
ative positions of TR DBD heterodimer and LBD dimer surfaces are shown in
schematic at top. Panels represent luciferase activities assayed in U937 cells
transfected with respective TRE-regulated reporters (4 g) and TR or TR
mutant expressionvectors (2g) and treated106MT3, as in Fig. 4. Thedata
show the average of five experiments.WT, wild type.
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does not rely upon DBD-DBD contacts. Second, TR action at
DR-4 requires both surfaces, consistent with the notion that
RXR-TRs are active, with their respective DBDs engaged in
interactions similar to those in the RXR-TR DBD x-ray struc-
ture (44). Finally, the fact that T3 response at Pal is independent
of both interfaces suggests that homo- and heterodimer forma-
tion is not needed for T3 response at this element and that
monomers are active.
Evidence for TR Homodimer Activity and Formation in
MammalianCells—TheTRDBDCTE,whichmakes auxiliary
contacts with DNA (44), was required for homodimer forma-
tion and T3 response at F2. Deletion of part of the TR DBD
CTE (the T-box) abolished TR homodimer formation at F2 and
DR-4, but only weakly inhibited RXR-TR heterodimer forma-
tion (Fig. 5A). In transfections, the T-box deletion inhibited T3
response at F2, where homodimer formation is preferred, but
exhibited a lesser effect at DR-4, where RXR-TR formation is
preferred (Fig. 5B).
Transfected RXR was not compatible with T3 response at F2
(Fig. 6). RXR did not affect T3 response at DR-4, but inhibited
T3 response at F2 by about 50%. Similar results were also
obtained in other cell types (not shown). RXR did enhance the
activity of a reporter that contained an RXR response element
(DR-1) in the presence of RXR ligand (9-cis-retinoic acid), con-
firming that it is expressed in functional form. The fact that
RXR overexpression reduces T3 response at F2 represents fur-
ther suggestive evidence that RXR-TRs are not active at this
element and that TR-TR homodimers are active.
We also confirmed that TR can self-associate in transfected
cells. We introduced expression vectors for TRs with in-frame
N-terminal FLAG and Myc peptide tags into U2-OS cells. Fig. 7
shows that theTRMycepitope isdetectable afterprecipitationof
transfected cell extracts with an anti-FLAGantibody. This finding
indicates that TR-TR interactions can occur in living cells.
Mutation of the LBDDimer SurfaceAffects T3 Sensitivity—Fi-
nally, we examined the relationships between requirements for
the LBD dimerization surface at different TREs and response
element-selective effects on T3 dose response. Analysis of the
amounts of T3 required for the half-maximal response at each
TRE confirms that TR action at F2 exhibits a higher EC50 than
at DR-4 (9) and extends these studies to show that similar
amounts of T3 are required for half-maximal response at DR-4
and Pal (Fig. 8). The same data show that mutation of the TR
LBD dimer surface enhanced T3 sensitivity at F2 and reduced
T3 sensitivity at DR-4. Thus, interactions at the LBD dimer
surface influence T3 dose response even though this mutation
does not affect the affinity of TR for T3 (17). Because RXR-TR
heterodimers are active at DR-4, TRmonomers at Pal, and TR
homodimers at F2, we propose that different TR oligomers
exhibit differential sensitivity to T3 in mammalian cells, with
RXR-TRs and TR monomers TR homodimers.
FIGURE 5. Deletion of the TR T-box blocks homodimer formation on
DNAand inhibits TR action at F2. A shows a gel shift assay comparing bind-
ing of TR and TR T-box deletion mutant to DR-4 and F2, as homodimers
(Ho) and heterodimers (He) with RXR. B, results of transfection analysis com-
paringTR andTRT-boxdeletionmutant activity atDR-4 andF2elements in
U937 monocytes, average of six experiments.
FIGURE 6. RXR inhibits T3 response at F2. Fold T3 activation obtained at
different TREs in the presence of transfected TR RXR in U937 monocytes.
In parallel, RXR action at a cognate DR-1-driven reporter is shown.
FIGURE 7. TR self-associates in transfected cells. Blot of an SDS-polyacryl-
amide gel used to separate extracts of cells transfected with FLAG  Myc-
taggedTRs andprobedwith ananti-Mycantibodyafter immunoprecipitation
with anti-FLAG antibody is shown. The 52-kDa species marked with an aster-
isk is present in nontransfected cell extracts and does not correspond to TR.
FIGURE 8. Differential T3 concentration sensitivity at different reporters
is reversedbyadimer surfacemutation.Averagedoseof T3 that is required
for half-maximal activation (EC50) at DR-4, F2, and Pal in U937 cell transfec-
tions performed with 2 g of TR or TRL422R expression vector.
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DISCUSSION
The findings reported in this study indicate that RXR-TRs
are not the only species of TR that is capable of transducing T3
signals in eukaryotic cells; homodimers and monomers also
play a role. We stress that our data support the notion that
RXR-TRs are important players in T3 response (1–4, 25,
46–53). RXR-TRs mediate T3 activation at DR-4 in yeast, and
T3 activation at DR-4 in mammalian cells is uniquely depend-
ent on the LBD dimer surface and the TR DBD heterodimer
surface, consistent with the notion that heterodimers are active
(Figs. 3 and 4). This does not seem to be the case at other TREs.
TR activates transcription strongly at F2 in mammalian cells,
but TR does not, correlating with the extent of homodimer
formation in vitro. Moreover, TR homodimers are active at F2
in yeast; TR activates transcription from this element in the
presence of GRIP1 and the absence of RXR, and these effects
require the LBD dimer surface. Finally, in mammalian cells: 1)
TRs exhibit a strong requirement for the LBD dimer surface at
F2, excluding the possibility that monomers are involved; 2) a
TR T-box deletion that strongly inhibits homodimer forma-
tion but not heterodimer formation onDNAselectively inhibits
TR action at F2; and 3) RXR inhibits T3 response at F2, sug-
gesting that heterodimer formation inhibits T3 response at
this element. Together, these findings suggest that TR-TR
homodimers are active at F2, and accordingly, TR-TR
homodimer formation can be detected in coimmunoprecipi-
tation experiments with tagged TRs from extracts of living
cells.
There may also be roles for monomers. A mutant version of
TR that only formsmonomers, TRL422R, activates transcrip-
tion with moderate efficiency at all three TREs in the presence
of GRIP1 in yeast, and almost as efficiently RXR-TRs at Pal in
this cell type. Furthermore, T3 response at Pal in mammalian
cells is completely independent of the LBD dimer and DBD
heterodimer surfaces.
Our results complement recent findings of another group
(34). Here, knockdown of endogenous RXR expression with
specific short interfering RNA only impaired transcription of a
subset of T3-regulated genes in a murine preneuronal cell line,
suggesting that RXR requirements of endogenous genes are
quite variable and that other TR species must be active.
Although the data reveal significant correlation between
DNA binding preferences of different TR oligomers and their
respective roles in transcriptional activation from different
response elements, our data also suggest that unknown influ-
ences must favor TR homodimer and monomer interactions
with their preferred TREs in mammalian cells. The fact that
TR homodimers and RXR-TRs activate transcription from F2
and DR-4 in yeast and mammalian cells and the ability of TR
monomers to activate transcription at Pal in mammalian cells
correlates well with observed DNA binding preferences of each
species in vitro. Nevertheless, RXR-TRs predominate in mam-
malian cell extracts, bind a variety of TREs in vitro, and even
activate transcription at Pal in yeast, so it is somewhat puzzling
that RXR-TRs only appear able to activate from the DR-4 ele-
ment in mammalian cell transfections. One obvious explana-
tion is that TR transfection alters the TR/RXR ratio to highlight
effects of homodimers and monomers. We find, however, that
the TRCTEmutant that is defective in homodimer formation
exhibits impairedT3 response at low levels of transfected recep-
tor (Fig. 5) (data not shown) and that even low amounts of TRs
function as monomers at Pal (Fig. 3). Thus, actions of TR
homodimers and monomers seem to be favored at particular
TREs over the predominant RXR-TR species by unspecified
mammalian cell factors. Perhaps stabilizing effects of
coregulators on TR DNA binding activity contribute to this
effect (32).
What is the physiological importance of our findings?
Although we believe that it is likely that RXR-TRs mediate
many or even most T3 responses in living cells, our data raise
the interesting possibility that alternate TR species play spe-
cial roles at subsets of TREs and that these influences could
expand the range and complexity of physiological responses
to T3. For example, the fact that TR-TR homodimers are
active at F2, coupled with results described herein and in
previous publications (9), suggests that this species must be
both resistant to hormone activation and highly active in the
presence of saturating levels of T3. Thus, TR homodimers
may confer a large dynamic range of responses to high levels
of T3 on particular subsets of target genes with F2-like ele-
ments. Our data have not yet revealed similar selective
actions for TR monomers; T3 responses at Pal are qualita-
tively similar to those at DR-4, but it remains possible that
TRE-selective actions of monomers will also be observed at
some Pal elements or at variant TREs with single AGGTCA
half-sites (54).
We recognize that our findings only indicate that contribu-
tions of different oligomeric forms of TR are possible and that
direct proof that RXR-TRs, TR-TR homodimers, and TR
monomers are active at particular genes in particular contexts
awaits further analysis. Itwill be particularly instructive to bring
chromatin immunoprecipitation to bear on this question. It is
already established that RXR-TRs occupy promoters of T3-ac-
tivated genes with DR-4 elements in the frog but that TRs can
occupy an unusual human immunodeficiency virus type 1 in
the absence of RXRs in a frog oocyte chromatin assembly assay
(26, 31). It nevertheless remains important to examine this
question in the context of mammalian genes. It may be possible
to determinewhether variable RXR dependence of endogenous
T3-responsive genes in mouse preneuronal cells correlates
with the lack of RXR recruitment to target promoters or par-
ticular TRE sequence organization (34). More generally, it will
be interesting to determine the degree of overlap between chro-
mosomal TR- and RXR-binding sites using a chromatin immu-
noprecipitation approach combined with nested oligonucleo-
tides that span the genome, as demonstrated with estrogen
receptors (55).
Finally, we stress that our studies do not exclude the possi-
bility that the TRE sequence could influence TR activity in
other ways. Half-site placement could influence TR activity via
effects on TR conformation; it is known that TR-TR
homodimers bind quite strongly to subsets of DR-4 elements
(39), and examination of likely orientations of the TR DBDs at
IP-6 and DR-4 elements indicates that one DBDmust swivel to
contact DNA at DR-4 (1). These conformational adaptations
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could exert profound influences on TR activity. Variations in
half-site spacing could also play a role (22, 56). Altered half-site
spacing can reverse the direction of retinoid response from
activation to repression by altering the polarity of RXR-retinoic
acid receptor pairs (57). Although analogous effects have not
been seen for TRs, it is known that differences in half-site spac-
ing of inverted palindromicTREs do affect ligand response. The
SERCa2 promoter contains a DR-4 element that is important
for T3 activation (TRE1) and two auxiliary inverted palin-
dromic elements (TRE2, IP-4 and IP-6, TRE3) (12). When TR
activity is assayed in isolation at the SERCa2 IPs, T3 activates
transcription from TRE3 but not TRE2, and the TR isoform-
selective modulator GC-1 exhibits strong aberrant antagonist
activity at TRE3 and weak antagonist activity at TRE2. Finally,
DNA contacts are known to exert allosteric influences on
nuclear receptor DNA binding domains that can then be prop-
agated to neighboring transactivation functions (58). Thus,
degenerate TRE sequences could influence receptor conforma-
tion and activity, even within the context of a standard TRE
organization.
In summary, however, our findings confirm that the effects of
TRE half-site placement on TR oligomer recruitment is at least
one important factor that should be considered in the regula-
tion of T3 responsiveness in vivo. It is noteworthy that unusual
actions of TR isoform-selective modulators have been
detected at IP elements (11, 12); GC-1 represses transcription
from IP elements in the SERCa2 promoter, and GC-24 is spe-
cifically superactive at F2. It will be interesting to examine the
possibility that these effects are related to preferential
homodimer recruitment, and whether it will be possible to
develop TRE-selective modulators by targeting drugs toward
particular TR species.
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